Silence Therapeutics (NASDAQ:SLN) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research note released on Friday morning, Benzinga reports. They currently have a $75.00 price objective on the stock.

Several other analysts also recently issued reports on SLN. Morgan Stanley restated an overweight rating and set a $45.00 price objective on shares of Silence Therapeutics in a report on Monday, April 22nd. Chardan Capital restated a buy rating and set a $42.00 price objective on shares of Silence Therapeutics in a report on Friday, May 17th. Finally, BMO Capital Markets started coverage on Silence Therapeutics in a report on Wednesday, January 31st. They set an outperform rating and a $67.00 price objective on the stock.

Silence Therapeutics Stock Down 0.4 %

Shares of NASDAQ:SLN traded down $0.09 during midday trading on Friday, reaching $21.91. The company had a trading volume of 43,820 shares, compared to its average volume of 132,535. Silence Therapeutics has a one year low of $4.84 and a one year high of $27.72. The stock’s fifty day moving average price is $22.02 and its 200-day moving average price is $19.47.

Silence Therapeutics (NASDAQ:SLN) last released its earnings results on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.18. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. The firm had revenue of $15.73 million during the quarter, compared to analyst estimates of $4.53 million. On average, equities research analysts anticipate that Silence Therapeutics will post -1.33 EPS for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in Silence Therapeutics in the 4th quarter valued at $110,000. Parkman Healthcare Partners LLC grew its holdings in Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after buying an additional 40,063 shares in the last quarter. Lynx1 Capital Management LP acquired a new stake in shares of Silence Therapeutics during the 3rd quarter worth $2,315,000. Vivo Capital LLC acquired a new stake in shares of Silence Therapeutics during the 4th quarter worth $8,862,000. Finally, Janus Henderson Group PLC acquired a new stake in shares of Silence Therapeutics during the 1st quarter worth $13,575,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.